Legend-Backed Immunotherapy Firm Shanghai Cell Therapy Group Co. Secures $136M Series C Round

Login to View

Shanghai Cell Therapy Group Co., a Chinese biotech company, has completed an RMB925 million (US$135.71 million) series C round of financing, led by China Pacific Insurance Company, Haier Capital and China Industrial Asset Management Limited, according to an announcement yesterday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in